Repligen (RGEN) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $178.20 -0.04%
Financial Fact:
Income tax provision: 1.06M
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
Income tax provision: 1.06M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Repligen (NASDAQ: RGEN) reported Q3 EPS of $0.08, in-line with the analyst estimate of $0.08. Revenue for the quarter came in at $24.7 million versus the consensus estimate of $24.39 million.
GUIDANCE:
Repligen sees FY2016 EPS of $0.42-$0.48, versus the consensus of $0.44. Repligen sees FY2016 revenue of $102-105 million, versus the consensus of $104.0 million.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BillionToOne, Inc. (BLLN) Tops Q3 EPS by 23c; Offers Guidance
- Relay Therapeutics, Inc. (RLAY) Tops Q3 EPS by 3c
- Red Violet (RDVT) Tops Q3 EPS by 6c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
